In Vitro and In Vivo Metabolic Activation of Obacunone, A Bioactive and Potentially Hepatotoxic Constituent of Dictamni Cortex

Abstract

Obacunone is one of the major bioactive constituents from Dictamni cortex, a traditional Chinese medicine widely used in China. Oral administration of obacunone or Dictamni cortex extract has been shown to cause liver injury in rats. Given that obacunone contains a furan ring, which is a structural alert, metabolic activation might be responsible for obacunone-induced liver injury. In this study, bioactivation pathways of obacunone in rat and human liver microsomes were investigated. Obacunone was first metabolized into cis-butene-1,4-dial, and then cis-butene-1,4-dial was captured by glutathione, N-acetyl-cysteine, and N-acetyl-lysine in the microsomal incubation system. A total of 13 adducts derived from the reaction of cis-butene-1,4-dial with glutathione and/or N-acetyl-lysine were detected and structurally identified by liquid chromatography coupled to high-resolution tandem mass spectrometry. The major metabolite (M7) was identified to be the cyclic mono-glutathione conjugate of cis-butene-1,4-dial, which was detected in bile and urine of obacunone-treated rats. M9 and M10, obacunone-derived glutathione-cis-butene-1,4-dial-NAL conjugates, were detected in the microsomal incubations of obacunone fortified with glutathione and N-acetyl-lysine as trapping agents. M3 and M4, pyrroline-2-one derivatives, were also detected in microsomal incubations. Further phenotyping studies indicated that ketoconazole showed a strong inhibitory effect on the production of cis-butene-1,4-dial in a concentration-dependent manner. CYP3A4 was demonstrated to be the primary enzyme responsible for the bioactivation of obacunone by using individual recombinant human CYP450 enzymes. The current study provides an overview of CYP450-dominated bioactivation of obacunone and contributes to the understanding of the role of bioactivation in obacunone-induced liver injury.

Key words

Obacunone - cis-butene-1,4-dial - CYP3A4 - Dictamni cortex - Dictamnus dasycarpus - Rutaceae - metabolic activation

• References

• 1 Lv MY, Xu P, Tian Y, Liang JY, Gao YQ, Xu FG, Zhang ZJ, Sun JB. Medicinal uses, phytochemistry and pharmacology of the genus Dictamnus (Rutaceae). J Ethnopharmacol 2015; 171: 247-263
• 2 Chang JB, Lan ME, Yang M, Heinrich M. A hexa-herbal TCM decoction used to treat skin inflammation: an LC-MS-based phytochemical analysis. Planta Med 2016; 82: 1134-1141
• 3 Efferth T, Schottler U, Krishna S, Schmiedek P, Wenz F, Giordano FA. Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature. Arch Toxicol 2017; 91: 1833-1846
• 4 Fan QY, Zhao BS, Wang CG, Zhang JX, Wu JY, Wang T, Xu AL. Subchronic toxicity studies of Cortex Dictamni extracts in mice and its potential hepatotoxicity mechanisms in vitro . Molecules 2018; 23: 2486
• 5 Wang LL, Li ZQ, Li L, Li YL, Yu M, Zhou YF, Lv XY, Arai H, Xu Y. Acute and sub-chronic oral toxicity profiles of the aqueous extract of Cortex Dictamni in mice and rats. J Ethnopharmacol 2014; 158 (Pt. A): 207-215
• 6 Wang XJ, Xu LP, Wang M. Hepatotoxicity caused by commonly-used Chinese medicinal herbs and compound preparation. J Cap Med Univ 2007; 28: 220-224
• 7 Li ZQ, Jiang LL, Zhao DS, Zhou J, Wang LL, Wu ZT, Zheng X, Zhi ZQ, Li P, Li HJ. The modulatory role of CYP3A4 in dictamnine-induced hepatotoxicity. Front Pharmacol 2018; 9: 1033
• 8 Wang QP, Liu HL, Slavsky M, Fitzgerald M, Lu C, OʼShea T. A high-throughput glutathione trapping assay with combined high sensitivity and specificity in high-resolution mass spectrometry by applying product ion extraction and data-dependent neutral loss. J Mass Spectrom 2019; 54: 158-166
• 9 Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011; 24: 1345-1410
• 10 Brink A, Pähler A, Funk C, Schuler F, Schadt S. Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. Drug Discov Today 2017; 22: 751-756
• 11 Kang P, Dalvie D, Smith E, Renner M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. Chem Res Toxicol 2009; 22: 106-117
• 12 Bauman JN, Frederick KS, Sawant A, Walsky RL, Cox LM, Obach RS, Kalgutkar AS. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos 2008; 36: 1016-1029
• 13 Erve JC, Maynard JW, Tonn G, Svensson MA, Tonn G, Quinn KP. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Chem Res Toxicol 2013; 26: 926-936
• 14 Li X, Zhong K, Guo Z, Zhong DF, Chen XY. Fasiglifam (TAK-875) inhibits hepatobiliary transporters: A possible factor contributing to fasiglifam-induced liver injury. Drug Metab Dispos 2015; 43: 1751-1759
• 15 Chidambara Murthy KN, Jayaprakasha GK, Patil BS. Obacunone and obacunone glucoside inhibit human colon cancer (SW480) cells by the induction of apoptosis. Food Chem Toxicol 2011; 49: 1616-1625
• 16 Tanaka T, Maeda M, Kohno H, Murakami M, Kagami S, Miyake M, Wada K. Inhibition of azoxymethane-induced colon carcinogenesis in male F344 rats by the citrus limonoids obacunone and limonin. Carcinogenesis 2001; 22: 193-198
• 17 Tanaka T, Kohno H, Tsukio Y, Honjo S, Tanino M, Miyake M, Wada K. Citrus limonoids obacunone and limonin inhibit azoxymethane-induced colon carcinogenesis in rats. Biofactors 2000; 13: 213-218
• 18 Ren W, Xin SK, Han LY, Zuo R, Li Y, Gong MX, Wei XL, Zhou YY, He J, Wang HJ, Si N, Zhao YY, Yang J, Bian BL. Comparative metabolism of four limonoids in human liver microsomes using ultra-high-performance liquid chromatography coupled with high-resolution LTQ-Orbitrap mass spectrometry. Rapid Commun Mass Spectrom 2015; 29: 2045-2056
• 19 Ren W, Li Y, Zuo R, Wang HJ, Si N, Zhao HY, Han LY, Yang J, Bian BL. Species-related difference between limonin and obacunone among five liver microsomes and zebrafish using ultra-high-performance liquid chromatography coupled with a LTQ-Orbitrap mass spectrometer. Rapid Commun Mass Spectrom 2014; 28: 2292-2300
• 20 Peterson LA. Reactive metabolites in the biotransformation of molecules containing a furan ring. Chem Res Toxicol 2013; 26: 6-25
• 21 Yu JH, Deng P, Zhong DF, Chen XY. Identification of animoacid and glutathione N-conjugated of toosendanin: bioactivation of furan ring mediated by CYP3A4. Chem Res Toxicol 2014; 27: 1598-1609
• 22 Lin DJ, Li CY, Peng Y, Gao HY, Zheng J. Cytochrome P450-mediated metabolic activation of diosbulbin B. Drug Metab Dispos 2014; 42: 1727-1736
• 23 Druckova A, Mernett JJ. Characterization of animoacid adducts of the enedial derivative of teucrin A. Chem Res Toxicol 2006; 19: 1330-1340
• 24 Chinese Pharmacopeia Commission. Pharmacopoeia of the Peopleʼs Republic of China, Vol. 1. Beijing: Medical Science Press; 2010
• 25 Lu D, Sullivan MM, Phillips MB, Peterson LA. Degraded protein adducts of cis-2-butene-1,4-dial are urinary and hepatocyte metabolites of furan. Chem Res Toxicol 2009; 22: 997-1007
• 26 Liu W, Li S, Wu YK, Yan X, Zhu YM, Huang JH, Chen Z. Metabolic profiles of neratinib in rat by using ultra-high-performance liquid chromatography coupled with diode array detector and Q-Exactive Orbitrap tandem mass spectrometry. Biomed Chromatogr 2018; 32: e4272
• 27 Zhu YT, Li L, Zhan G, Wan H, Yang CY, Diao XX, Chen XY, Zhang LS, Zhong DF. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B 2016; 1033 – 1034: 117-127